Alexion Pharmaceuticals has agreed to buy Portola Pharmaceuticals for $1.41 billion.
The deal, where Alexion will pay $18 a share for the acquisition, is expected to help Alexion boost its portfolio by including Portola's coagulation factor Xa drug Andexxa. "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5," Alexion Chief Executive Ludwig Hantson said in a statement.
The acquisition is expected to in the third quarter. However, it is subject to approval by holders of a majority of Portola shares outstanding and by regulators.
a developer of biologic therapeutic products
Industry NotClassified